Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study

Choi, Jee Woong; Kim, Yul Hee; Kwak, Hyunbin; Park, Jin; Lee, Won‐Soo; Kang, Hoon; Kim, Jung Eun; Yoon, Tae–Young; Kim, Ki‐Ho; Jang, Yo-Soon; Kim, Do Won; Kim, Moon‐Bum; Lew, Bark Lynn; Sim, Woo‐Young; Jeon, Jiehyun; Seo, Soo Hong; Kwon, Oh Sang; Huh, Chul; Lee, Dongyoun; Lee, Yang Won; Park, Byung Cheol; Won, Chong Hyun; Kim, Doyoung; Kim, Hyojin; Kim, Beom Joon; Lee, Young; Kim, Sang Seok; Choi, Gwang‐Seong

doi:10.5021/ad.21.202

Cited by 10 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, with patients enrolled from 22 hospitals, most AA patients were of mild severity (followed by severe and moderate severity), were male (53.7%), and most were aged between 10 and 14 years (38.1%). This study also pointed out that patients with severe AA (as well as their families) are experiencing a poor quality of life [8]. Another retrospective observational study shows that 34.8% have moderate-to-severe forms, and only 15.1% are mild.…”

Section: Discussionmentioning

confidence: 54%

“…A hospitalbased multicenter study conducted in Korea reported that quality of life worsened in family members and pediatric patients as the severity of the disease increased. This study also reported that as the disease progressed, the annual cost of treatment in most patients was over 1000 $ [8]. Patients affected by this pathology, both adults and children, were often (compared to controls defined as healthy adults) diagnosed with anxiety and/or depression (or symptoms) [9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Economic Burden of Alopecia Areata in Romania

Strilciuc,

Olteanu,

Lăpădatu

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Alopecia areata is a skin disease that affects patients’ quality of life and social participation. Objective: To quantify the economic burden of alopecia areata and to map health services utilization among patients with alopecia areata.Materials and methods: Prospective and retrospective data sources, using both top-down and bottom-up approaches to estimate direct and indirect costs and to map health service utilization associated with alopecia areata in Romania in 2022.Results: In our study, the total cost of alopecia areata in Romania for 2022 was estimated at 46.289 million EUR for adult patients and 1.89 million EUR for pediatric patients, encompassing both mild and severe cases. The breakdown reveals that both mild and severe cases incurred the highest costs due to associated expenses, medical services, and treatment. As for children, the highest alopecia-related expenses were represented by associated expenses and treatment costs (for both severity levels).Conclusion: This is the first study to quantify the burden of alopecia areata in Romania. Additional studies are needed due to a low sample size. However, considering our estimations based on external data sources, alopecia areata should be considered when planning health service distribution.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Introductionmentioning

confidence: 99%

The Economic Burden of Alopecia Areata in Romania

Strilciuc,

Olteanu,

Lăpădatu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Of note, 90 patients with FPHL revealed that the expenditure was related to QoL, which is the same findings as our study. Choi et al 36 indicated the medical consumption of pediatric AA patients. Two-thirds of severe AA patients spent more than $1,000 a year, and the number of clinic visits increased as the severity of AA increased.…”

Section: Discussionmentioning

confidence: 99%

The Quality of Life and Psychosocial Impact on Female Pattern Hair Loss

Hwang,

Ryou,

Jeong

et al. 2024

Ann Dermatol

Self Cite

View full text Add to dashboard Cite

Background Alopecia, a benign dermatologic condition affecting both genders, particularly harms female patients due to psychosocial effects. Female pattern hair loss (FPHL), the primary cause of hair loss in women, lacks sufficient Korean epidemiological studies examining its psychosocial aspects. Objective This study aimed to explore FPHL’s psychosocial impacts, including quality of life (QoL), depression, anxiety, medical consumption, and hair loss factors in Korean women. Methods A total of 202 patients with FPHL were interviewed using a validated questionnaire to assess the QoL, psychological impact, and pattern of medical consumption. The severity of hair loss was evaluated using the “basic and specific (BASP) classification” by dermatologists. The Hair-Specific Skindex-29 (HSS29) was used to assess the QoL and Beck depression inventory (BDI), Beck anxiety inventory (BAI) to evaluate psychological aspects, and medical expenses and the number of clinic visits to determine medical consumption. Results The global HSS29 score of FPHL was 40.97±18.92, indicating a notable impact on QoL. The mean BDI and BAI scores were 14.47 and 10.06, respectively. In multivariable regression analysis, HSS29, BDI, and BAI scores were most affected by the severity of hair loss ( p <0.001). Conclusion FPHL damages the psychosocial aspects of patients, such as QoL, depression, and medical consumption, according to the severity of hair loss.

show abstract

Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study

David,

Shokrian,

Del Duca

et al. 2024

Arch Dermatol Res

View full text Add to dashboard Cite

Alopecia areata (AA) is nonscarring hair loss characterized by Th1 and concomitant Th2 skewing, particularly in atopic patients. Despite novel developments for adult AA, safe and effective treatments for pediatric patients remain limited. Dupilumab, with a well-studied safety profile, may have therapeutic potential for atopic pediatric AA. To evaluate the ability of dupilumab to regrow hair in pediatric AA patients. We conducted a single-center, retrospective, observational study to evaluate hair regrowth [using Severity of Alopecia Tool (SALT)] with dupilumab in 20 children with both AD and AA (age range 5–16 years, mean 10.8 years; baseline SALT range 3–100, mean 54.4). Patient demographics, atopic history, IgE and SALT scores were collected at 12wk follow-up visits, up to > 72wks, to evaluate hair regrowth. Spearman correlations with clinical data were performed. Patients showed clinical improvement over the follow-up period (range 24 to > 72wks, mean 67.6wks) with significant mean(± SD) reduction in SALT at 48wks versus baseline [20.4(± 35.1) vs 54.4(± 37.6), respectively; p < 0.01] and continued improvement up to > 72wks [2.2(± 4.9), p < 0.01]. Baseline SALT positively correlated with disease duration (r = 0.54, p < 0.01), and negatively correlated with improvement in SALT at weeks 24, 36, and 48 (|r|≥ 0.65, p < 0.01 for all comparisons). Baseline IgE positively correlated with improvement in SALT at week 36 (r > 0.60, p < 0.05). Dupilumab was well-tolerated, with no new safety concerns. These real-world data support the utility of dupilumab to safely treat pediatric AA patients, corroborating the role of Th2 skewing in children with AA and associated atopy, warranting larger clinical trials.

show abstract

Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study

Cited by 10 publications

References 23 publications

The Economic Burden of Alopecia Areata in Romania

The Economic Burden of Alopecia Areata in Romania

The Quality of Life and Psychosocial Impact on Female Pattern Hair Loss

Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study

Contact Info

Product

Resources

About